Embattled pain drug developer QrXPharma has sent mixed messages to the market, urging shareholders to vote against a spill of two directors proposed by disgruntled investor Lang Walker, while also flagging it was considering giving up on its technology.
The company has set a general meeting date of July 7, giving the property development mogul a month to convince shareholders to support the axing of QrXPharma chairman and ResMed founder Peter Farrell and the company’s founder Gary Pace.
Loading...
Jessica Gardner is The Australian Financial Review’s United States correspondent. She was previously deputy editor - news. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
